3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Interventions
Carboplatin
127
pembrolizumab
123
Cisplatin
112
Paclitaxel
102
Gemcitabine
83
Specimen Handling
80
Magnetic Resonance Spectroscopy
80
Docetaxel
69
Dexamethasone
59
Cyclophosphamide
59
Pemetrexed
54
Bevacizumab
54
Doxorubicin
52
durvalumab
51
Radiotherapy
49
Capecitabine
48
Radiation
47
Oxaliplatin
47
Fluorouracil
47
Rituximab
42
Leucovorin
42
Vincristine
41
Lenalidomide
39
Etoposide
38
atezolizumab
35
Nivolumab
35
Letrozole
35
Prednisone
31
Bortezomib
31
130-nm albumin-bound paclitaxel
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
fludrocortisone acetate
×
90 days
×
Clear all
NCT06136650
2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled